argenx SE
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
15 jul 2015 - 18:21
Statutaire naam
argenx SE
Titel
arGEN-X N.V. announces change to the Board of Directors
Bericht
Breda, the Netherlands/Ghent, Belgium, 15 July 2015 - arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announces that non-executive director Michael B. Sheffery, representing Orbimed Advisors, will resign from the Board of Directors per 26 August 2015.
Datum laatste update: 23 december 2025